These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 9269642

  • 1. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK, Slatopolsky EA, Goldberg DI.
    Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
    [Abstract] [Full Text] [Related]

  • 2. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK.
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [Abstract] [Full Text] [Related]

  • 3. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
    Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI.
    Nephrol Dial Transplant; 1997 May; 12(5):961-4. PubMed ID: 9175050
    [Abstract] [Full Text] [Related]

  • 4. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA, Burke SK, Dillon MA.
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [Abstract] [Full Text] [Related]

  • 5. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E.
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [Abstract] [Full Text] [Related]

  • 6. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 Jan; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM.
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [Abstract] [Full Text] [Related]

  • 8. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriu A.
    Nephron Clin Pract; 2004 Jan; 97(1):c17-22. PubMed ID: 15153763
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
    Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E.
    Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142
    [Abstract] [Full Text] [Related]

  • 11. Renagel: reducing serum phosphorus in haemodialysis patients.
    Burke SK.
    Hosp Med; 2000 Sep; 61(9):622-7. PubMed ID: 11048603
    [Abstract] [Full Text] [Related]

  • 12. Renagel: a new and different phosphate binder.
    Ramsdell R.
    ANNA J; 1999 Jun; 26(3):346-7. PubMed ID: 10633608
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM, Reiner D, Kern M, Burke S.
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [Abstract] [Full Text] [Related]

  • 19. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.
    Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, Tzallas CS, Elisaf MS, Pappas MV, Siamopoulos KC.
    Perit Dial Int; 2006 Dec; 26(3):320-7. PubMed ID: 16722024
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.